*Inclusion criteria for parent clinical trial*: The trial from which the patients in this case-control study were identified was MA.27. Inclusion criteria included postmenopausal women with histologically confirmed and completely resected invasive breast cancer with surgical margins clear of invasive carcinoma in the following TMN categories (AJCC Version 6): pT1, pT2, pT3; pNx, pN0, pN1, pN2, pN3 (only when the sole basis is presence of 10 or more involved axillary nodes); MO. The primary tumor must have been ER and/or progesterone receptor positive.
Item
*Inclusion criteria for parent clinical trial*: The trial from which the patients in this case-control study were identified was MA.27. Inclusion criteria included postmenopausal women with histologically confirmed and completely resected invasive breast cancer with surgical margins clear of invasive carcinoma in the following TMN categories (AJCC Version 6): pT1, pT2, pT3; pNx, pN0, pN1, pN2, pN3 (only when the sole basis is presence of 10 or more involved axillary nodes); MO. The primary tumor must have been ER and/or progesterone receptor positive.
boolean
C1512693 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0007328 (UMLS CUI [1,3])
C1269815 (UMLS CUI [1,4])
C0242801 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
C0232970 (UMLS CUI [2,3])
C0043210 (UMLS CUI [2,4])
C0853879 (UMLS CUI [2,5])
C0679557 (UMLS CUI [2,6])
C0475288 (UMLS CUI [2,7])
C0332391 (UMLS CUI [2,8])
C0332392 (UMLS CUI [2,9])
C0332393 (UMLS CUI [2,10])
C0332401 (UMLS CUI [2,11])
C0332397 (UMLS CUI [2,12])
C0332398 (UMLS CUI [2,13])
C0332399 (UMLS CUI [2,14])
C0279754 (UMLS CUI [2,15])
C0279759 (UMLS CUI [2,16])
*Case Definition Breast Cancer Events*: The primary outcome evaluated was Breast Cancer Free Interval (BCFI), defined as the time from randomization to the first local-regional breast cancer recurrence (including ipsilateral ductal carcinoma in situ [DCIS]), distant breast cancer recurrence, contralateral breast cancer (invasive or DCIS) or death with or from breast cancer without prior recurrence date. Follow-up was censored at non-breast cancer death, or longest follow-up without recurrence. *Cases* were defined as those patients who experienced a BCFI event and *controls* were those patients who did not experience such an event.
Item
*Case Definition Breast Cancer Events*: The primary outcome evaluated was Breast Cancer Free Interval (BCFI), defined as the time from randomization to the first local-regional breast cancer recurrence (including ipsilateral ductal carcinoma in situ [DCIS]), distant breast cancer recurrence, contralateral breast cancer (invasive or DCIS) or death with or from breast cancer without prior recurrence date. Follow-up was censored at non-breast cancer death, or longest follow-up without recurrence. *Cases* were defined as those patients who experienced a BCFI event and *controls* were those patients who did not experience such an event.
boolean
C0678222 (UMLS CUI [1,1])
C1706256 (UMLS CUI [1,2])
C3274433 (UMLS CUI [1,3])
C0677874 (UMLS CUI [1,4])
C0872291 (UMLS CUI [1,5])
C1704788 (UMLS CUI [1,6])
C0034656 (UMLS CUI [1,7])
C0278493 (UMLS CUI [1,8])
C0007124 (UMLS CUI [1,9])
C0443203 (UMLS CUI [1,10])
C1306577 (UMLS CUI [1,11])
C1522577 (UMLS CUI [2,1])
C3889990 (UMLS CUI [2,2])
C4722463 (UMLS CUI [2,3])
C1518422 (UMLS CUI [2,4])
C0678222 (UMLS CUI [2,5])
C1513491 (UMLS CUI [2,6])
C1522577 (UMLS CUI [2,7])
C1532381 (UMLS CUI [2,8])
*Selection of Controls*: All patients who were treated on protocol and who had genotyping performed were utilized as controls. These patients came from 3 cohorts: Cohort 1: patients genotyped.
Item
*Selection of Controls*: All patients who were treated on protocol and who had genotyping performed were utilized as controls. These patients came from 3 cohorts: Cohort 1: patients genotyped.
boolean
C0009932 (UMLS CUI [1,1])
C0242802 (UMLS CUI [1,2])
C5551028 (UMLS CUI [1,3])
C1285573 (UMLS CUI [1,4])